ChartRow logo
Data provided bySource: Twelve Data
PeersMEDPNTRARVTYAWATMTD
Share this page

ILMN — Illumina Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ILMN be worth today? →
ILMN returns: By year · By month · By week · Trailing

Price data

Price
$207.01
YTD price return
+57.83%
YTD total return
+57.83%
Market cap
31.3B
Enterprise value
32.3B
Shares outstanding
151.2M
52W low
$112.65
52W high
$309.35
From 52W high
-33.08%
From 52W low
+83.76%
52W range
48%$113–$309
Beta
1.45

Volume

Rel volume
0.51×
30D volume
2.4M
30D $ vol
612.8M

Insider trading

Insider net 1W
−$61.2M
Insider net 1M
−$127.7M
Insider net 3M
−$415.9M
Insider net 1Y
−$720.4M

Form 4 transactions by trade date, as filed; latest on file 2026-11-11.

Fundamentals

Sales (ttm)
4.5B
Sales/share
$30.01
EPS (ttm)
$5.83
FCF (ttm)
1.1B
FCF/share
$6.99
Book value/share
$20.80
Net margin
19.72%
ROE
28.46%
ROA
13.14%
Debt / equity
0.57×
Current ratio
2.63

Growth (CAGR, ttm) · 10Y

Sales
+5.85%+0.54%+1.18%+6.72%
Net income
+27.60%n/a-0.24%+7.29%
FCF
+5.72%+84.63%+17.71%+6.88%
Shares
-1.05%-1.63%-0.66%+0.29%

Per-share growth (CAGR, ttm) · 10Y

EPS
+30.73%n/a-0.87%+6.92%
Sales/share
+6.97%+2.21%+1.86%+6.41%
FCF/share
+6.84%+87.69%+18.50%+6.58%
Book value/share
+33.62%-17.63%-21.11%+3.16%
Price
+72.67%+31.87%-11.11%+4.45%
Total return
+72.67%+31.87%-11.11%+4.45%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
35.5×
P/OI (ttm)
32.6×
Fwd P/E
34.4×
P/S (ttm)
6.9×
P/B (mrq)
10.0×
P/FCF (ttm)
29.6×
EV/EBITDA (fy)
26.1×
EV/Sales (ttm)
7.1×
FCF yield (ttm)
3.38%
Buyback yield (realized, 1y)
1.05%
Shareholder yield (realized, 1y)
1.05%
Buyback yield (cash, ttm)
1.20%
Shareholder yield (cash, ttm)
1.20%

Vs own 10Y history

P/E
20th
P/OI
19th
P/S
37th
P/B
54th
P/FCF
15th

Bar = where today’s multiple sits in ILMN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
-1.21%
5D
-2.87%
1M
-23.66%
3M
+7.46%
YTD
+57.83%
1Y
+72.61%
5Y
-44.50%
1D
-1.21%
5D
-2.87%
1M
-23.66%
3M
+7.46%
YTD
+57.83%
1Y
+72.61%
5Y
-44.50%

Fundamentals#

Revenue

5Y CAGR +6.0%10Y CAGR +6.9%YoY +4.2%
$4.5B TTM$1.1B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +6.8%10Y CAGR +2.8%YoY +34.4%
$960M TTM$305M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +4.1%10Y CAGR +5.8%YoY +45.9%
$5.83 TTM$1.43 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +0.9%10Y CAGR +3.8%YoY +49.8%
$1.1B TTM$379M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.2B, capex −$173M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $419M, capex −$40M

Shares (diluted)

5Y +5.4%10Y +4.7%YoY +0.0%
153.5M TTM154M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +5.3%10Y CAGR +6.3%YoY +46.7%
$895M TTM$220M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full ILMN financials →

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.

San Diego, CA·8,600 employees·Diagnostics & Research·illumina.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding ILMN#

25 of the 193 ETFs ChartRow carries live hold ILMN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF2.1%
ARKKARK Innovation ETF1.5%
IJHiShares Core S&P Mid-Cap ETF0.7%
MDYSPDR S&P MidCap 400 ETF Trust0.7%
VHTVanguard Health Care ETF0.4%
VBKVanguard Small-Cap Growth ETF0.4%
VXFVanguard Extended Market ETF0.3%
VBVanguard Small-Cap ETF0.3%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%